#United States #Duality Biologics #Adcendo ApS #antibody-drug conjugate #Princeton

Duality Biologics and Adcendo ApS: A Strategic Expansion in Cancer Treatment

In a major development for cancer therapeutics, Duality Biologics and Adcendo ApS have affirmed their commitment to revolutionizing cancer treatment by expanding their existing partnership. Announced on November 25, 2024, this collaboration reflects both companies' dedication to advancing next-generation antibody-drug conjugate (ADC) therapies aimed at addressing critical needs in cancer patient care.

The Expanded Collaboration

The strategic license agreement, initially established in January 2023, marked the start of a significant alliance between the two biotech companies. At that time, Adcendo opted to leverage Duality's proprietary DITAC (Duality Immune Toxin Antibody Conjugates) linker-payload platform for its uPARAP-ADC program, specifically targeting mesenchymal cancers that currently have a high unmet medical need. The latest announcement indicates that Adcendo has exercised its option to utilize Duality's technology for additional assets, further enriching its ADC pipeline.

Michael Pehl, CEO of Adcendo ApS, expressed enthusiasm regarding the extended collaboration, noting, “Our strategic collaboration with Duality allows us to progress with our aim to develop highly differentiated novel ADCs for the treatment of hard-to-treat cancers.” He underscored how this partnership enhances their abilities to develop pioneering ADCs, working toward providing innovative solutions to challenging medical issues faced by patients.

Likewise, John Zhu, Founder and CEO of Duality Biologics, highlighted the potential impact of their united strengths in ADC discovery and development, remarking, “Duality is dedicated to becoming a leading global next-generation ADC company.” Zhu emphasized the goal of using their leading-edge platform in partnership with Adcendo to create impactful ADC medicines for cancer treatment worldwide.

About Duality Biologics

Duality Biologics is known for its rigorous focus on the discovery and development of next-generation ADC therapeutics that address critical healthcare challenges across not only cancer, but also autoimmune diseases. The company's advancements in ADC technologies are currently supported by global intellectual property rights, underscoring its commitment to innovation and excellence in biopharmaceutical development. Duality's clinical-stage pipeline is illustrative of its success, with several ADCs already undergoing multi-regional clinical trials across more than 17 countries involving over 1,000 enrolled patients.

Furthermore, Duality continues to explore novel protein engineering approaches and unique ADC technologies. Their ambition includes the development of “Super ADCs,” which will incorporate bispecific ADCs and novel mechanisms of action targeting various diseases, including autoimmune conditions.

The expanded collaboration between Duality Biologics and Adcendo ApS signifies a promising advancement in cancer therapy, with both companies poised to make significant contributions to the field of ADC treatments. As they work together to bring innovative solutions to patients suffering from aggressive and hard-to-treat cancers, the medical community eagerly anticipates the results of their collaborative efforts.

This strategic partnership not only enhances the ADC pipeline of Adcendo but also establishes Duality's platform as a crucial resource in the development of future cancer therapies. With their combined efforts, both companies are likely to set new standards in effective cancer treatment methodologies and reaffirm their positions as innovators in the biotech space.